$33.12▴ 0.58%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.89cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
47th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+26.5%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
Invesco Nasdaq Biotechnology ETF turns 189¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year. Its valuation is around the middle of its own recent range. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$1.90
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin17.8%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$6.73B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days4 articles
1 bullish3 neutral0 bearish
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?Funkled and Focus Partner to Turn Financial Education into Advice-Ready Clients
What This Invesco Insider Move Signals With the Stock Up 63%
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?- Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.